Publications by authors named "Leonardo Calza"

Claim this Profile
A
All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry.
Andrea Giacomelli, Nicolò Capra, Riccardo Lolatto, Roberta Gagliardini, Tommaso Clemente, Leonardo Calza

Clin Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-cluster A and anti-p24 antibodies in people with multidrug-resistant HIV: Preliminary observations from the PRESTIGIO registry.
Tommaso Clemente, Mehdi Benlarbi, Rebecka Papaioannu Borjesson, Elisa Garlassi, Maria Cristina Moioli, Leonardo Calza

J Clin Virol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV infection among adolescents and young adults in Italy: Epidemiology, viro-immunological and treatment outcomes.
Francesco Maria Fusco, Ilaria Mastrorosa, Francesca Vichi, Adriana Cervo, Annalisa Saracino, Leonardo Calza

Int J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study.
Maria Mazzitelli, Claudia Cozzolino, Dina Yaacoub, Angela Pieri, Elke Erne, Leonardo Calza

J Antimicrob Chemother· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry.
Filippo Lagi, Michele Bellomo, Riccardo Lolatto, Filippo Ducci, Seble Tekle Kiros, Leonardo Calza

Viruses· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia.
Leonardo Calza, Vincenzo Colangeli, Maddalena Giglia, Claudio Rigamonti, Isabella Bon

J Acquir Immune Defic Syndr· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decrease in drug-drug interactions between antiretroviral drugs and concomitant therapies in older people living with HIV-1 switching to bictegravir/emtricitabine/tenofovir alafenamide.
Leonardo Calza, Maddalena Giglia, Alberto Zuppiroli, Silvia Cretella, Salvatore Vitale

New Microbiol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer in people with multidrug-resistant HIV.
Tommaso Clemente, Domenico Pontillo, Vincenzo Malagnino, Leonardo Calza, Antonio Di Biagio

AIDS· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Daniele Armenia, Vincenzo Spagnuolo, Maria C Bellocchi, Laura Galli, Leonardo Duca, Leonardo Calza

J Antimicrob Chemother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
Leonardo Calza, Maddalena Giglia, Vincenzo Colangeli, Isabella Bon, Salvatore Vitale

HIV Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
Tommaso Clemente, Sara Diotallevi, Riccardo Lolatto, Roberta Gagliardini, Andrea Giacomelli, Leonardo Calza

Int J Antimicrob Agents· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study.
Nicolò Corti, Barbara Menzaghi, Giancarlo Orofino, Marta Guastavigna, Filippo Lagi, Leonardo Calza

Viruses· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship Between Vitamin D Deficiency and Nonalcoholic Fatty Liver Disease in Patients With HIV-1 Infection.
Leonardo Calza, Maddalena Giglia, Pierluigi Viale

J Acquir Immune Defic Syndr· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years.
Leonardo Calza, Vincenzo Colangeli, Giorgio Legnani, Silvia Cretella, Isabella Bon

AIDS Res Hum Retroviruses· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Tommaso Clemente, Laura Galli, Riccardo Lolatto, Roberta Gagliardini, Filippo Lagi, Leonardo Calza

BMJ Open· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience.
Leonardo Calza, Vincenzo Colangeli, Giulia Pensalfine, Lucia Appolloni, Salvatore Vitale

Int J STD AIDS· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting.
Paolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Leonardo Calza

Viruses· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir.
Leonardo Calza, Isabella Bon, Giulia Pensalfine, Salvatore Vitale, Lucia Appolloni

J Acquir Immune Defic Syndr· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
Paolo Maggi, Giuseppe Vittorio De Socio, Barbara Menzaghi, Chiara Molteni, Nicola Squillace, Leonardo Calza

BMC Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people.
Nevio Taglieri, Rachele Bonfiglioli, Isabella Bon, Pietro Malosso, Andrej Corovic, Leonardo Calza

J Nucl Cardiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
Leonardo Calza, Giorgio Legnani, Ciro Fulgaro, Gabriella Verucchi, Isabella Bon

J Acquir Immune Defic Syndr· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV.
Daniele Armenia, Maria Mercedes Santoro, Maria Concetta Bellocchi, Luca Carioti, Laura Galli, Leonardo Calza

Int J Antimicrob Agents· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Leonardo Calza, Marco Borderi, Vincenzo Colangeli, Teresa Miani, Bianca Nuti

AIDS· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
Lucia Taramasso, Andrea De Vito, Elena Delfina Ricci, Giancarlo Orofino, Nicola Squillace, Leonardo Calza

AIDS Patient Care STDS· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restriction Factors expression decreases in HIV-1 patients after cART.
Vanessa D'Urbano, Alessia Bertoldi, Maria Carla Re, Elisa De Crignis, Martina Tamburello, Leonardo Calza

New Microbiol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis